You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD19 CHIMERIC RECEPTOR EXPRESSING T LYMPHOCYTES

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

CNS Lymphoma Trial in Duarte (procedure, biological, drug)

Recruiting
  • Central Nervous System Lymphoma
  • Aspiration
  • +10 more
  • Duarte, California
    City of Hope Medical Center
Dec 8, 2022

Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent WHO Grade II Glioma Trial in Duarte (Chlorotoxin

Recruiting
  • Recurrent Glioblastoma
  • +3 more
  • Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT delivery)
  • Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery)
  • Duarte, California
    City of Hope Medical Center
Feb 25, 2022

Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma Trial in Duarte (Acalabrutinib,

Recruiting
  • Recurrent Mantle Cell Lymphoma
  • Refractory Mantle Cell Lymphoma
  • Acalabrutinib
  • CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
  • Duarte, California
    City of Hope Comprehensive Cancer Center
Jun 16, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 Trial in Duarte

Not yet recruiting
  • Castration-Resistant Prostate Carcinoma
  • +2 more
  • Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
  • +7 more
  • Duarte, California
    City of Hope Medical Center
Apr 5, 2023

DLBCL, Not Otherwise Specified, Recurrent DLBCL, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma Trial in Seattle

Terminated
Has Results
  • Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
  • +5 more
  • Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 1, 2022

Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma Trial in

Recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +7 more
  • Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jul 14, 2022

Recurrent DLBCL, Recurrent Mantle Cell Lymphoma, Refractory DLBCL Trial in Duarte (Autologous

Active, not recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • +4 more
  • Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells
  • +2 more
  • Duarte, California
    City of Hope Medical Center
Mar 28, 2022

Ependymoma, Glioblastoma, Medulloblastoma Trial in Duarte (IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR

Recruiting
  • Ependymoma
  • +3 more
  • IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
  • Duarte, California
    City of Hope Medical Center
Mar 9, 2022

Malignant Brain Tumor, Recurrent Malignant Brain Tumor, Refractory Malignant Brain Tumor Trial in Duarte (Cyclophosphamide,

Recruiting
  • Malignant Brain Neoplasm
  • +2 more
  • Duarte, California
    City of Hope Medical Center
May 19, 2022

Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8 Trial in Duarte

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Autologous Anti-PSCA-CAR-4-1BB/TCRzeta-CD19t-expressing T-lymphocytes
  • +3 more
  • Duarte, California
    City of Hope Medical Center
Mar 17, 2022

Recurrent Glioblastoma, Refractory Glioblastoma Trial in Duarte (IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory

Recruiting
  • Recurrent Glioblastoma
  • Refractory Glioblastoma
  • IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Oct 29, 2021

Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small

Recruiting
  • Relapsed or Refractory CD19+ B-cell Lymphoma
  • +2 more
  • TBI-2001
  • +2 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Jul 26, 2023

Non-Hodgkin's Lymphoma, B-Cell ALL, B-Cell CLL Trial in Houston (CD19.CAR-CD28Z T Cells - dose escalation 2, CD19.CAR-CD28Z T

Recruiting
  • Non-Hodgkin's Lymphoma
  • +2 more
  • CD19.CAR-CD28Z T Cells - dose escalation 2
  • CD19.CAR-CD28Z T Cells - dose escalation 1
  • Houston, Texas
  • +1 more
Feb 10, 2022

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive Trial in Palo Alto

Not yet recruiting
  • Multiple Sclerosis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Palo Alto, California
    Stanford Multiple Sclerosis Center
Nov 13, 2023

Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV Trial in Denver,

Recruiting
  • Lupus Nephritis
  • +2 more
  • KYV-101 anti-CD19 CAR-T cell therapy
  • Standard lymphodepletion regimen
  • Denver, Colorado
  • +1 more
Jul 7, 2023

B Acute Lymphoblastic Leukemia Trial in Duarte (drug, procedure, other)

Not yet recruiting
  • B Acute Lymphoblastic Leukemia
  • Autologous Anti-CD19 CAR-expressing T Lymphocytes
  • +6 more
  • Duarte, California
    City of Hope Medical Center
Jan 30, 2023

Blood Cancer Trial (KCAT19 T cells)

Not yet recruiting
  • Blood Cancer
  • KCAT19 T cells
  • (no location specified)
May 20, 2022

Glioblastoma Multiforme of Brain Trial in Duarte (CHM-1101 CAR-T cells)

Not yet recruiting
  • Glioblastoma Multiforme of Brain
  • CHM-1101 CAR-T cells
  • Duarte, California
    City of Hope Medical Center
Dec 19, 2022

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Acute Lymphoid Leukemia, B-Cell Leukemia, Leukemia, Lymphocytic, B Cell Trial run by the National Cancer Institute (NCI)

Not yet recruiting
  • Acute Lymphoid Leukemia
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Aug 17, 2022

Non-Hodgkin Lymphoma Trial in Aurora (CD19x22 CAR T Cells)

Active, not recruiting
  • Non-Hodgkin Lymphoma
  • CD19x22 CAR T Cells
  • Aurora, Colorado
    University of Colorado Hospital
Sep 1, 2022

SLE (Systemic Lupus) Trial in Bangkok (CAR T-cell therapy)

Not yet recruiting
  • SLE (Systemic Lupus)
  • CAR T-cell therapy
  • Bangkok, Please Select, Thailand
    King Chulalongkorn Memorial Hospital
Nov 23, 2023

Hodgkin Lymphoma, Relapse, Refractory Trial in Chapel Hill (Chemotherapy, Cell infusion)

Not yet recruiting
  • Hodgkin Lymphoma
  • +2 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Oct 13, 2023

19 and 22+ B Cell Hematologic Tumors Trial in Wuhan (Autologous CD19/CD22 Chimeric Antigen Receptor T-cells)

Recruiting
  • 19 and 22+ B Cell Hematologic Tumors
  • 19 and 20+ B Cell Hematologic Tumors
  • Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells
  • Wuhan, Hubei, China
    Tongji Hospital
Jan 11, 2023

Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia, Lymphoma, B-Cell Trial run by the National Cancer Institute

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Anti-CD19 and anti-CD20 bicistronic CAR T- cells
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Apr 10, 2023